Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the human telomerase reverse transcriptase promoter-known to drive malignant transformation of <i>CTNNB1</i>-mutated HCA-seem to be dispensable for <i>RSPO2</i> rearranged HCA and HCC.
|
30901310 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mutation of the TERT promoter is one of the most common genetic alterations in hepatocellular carcinoma (HCC), indicating that TERT upregulation is a critical event in hepatocarcinogenesis.
|
30447097 |
2019 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Consistently, TERT expression levels in RNs were comparable to those in normal livers, whereas every HCC tissue demonstrated an elevated level of TERT expression.
|
30756187 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Part of the telomerase complex, telomerase reverse transcriptase, is encoded by TERT, and several mechanisms of telomerase reactivation have been described in HCC that include somatic TERT promoter mutations, TERT amplification, TERT translocation and viral insertion into the TERT gene.
|
31253940 |
2019 |
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although main HCC oncogenic drivers have been deciphered in recent years (TERT, TP53, CTNNB1 mutations, miR122 and CDKN2A silencing), therapeutic applications derived from this molecular knowledge are still limited.
|
31783782 |
2019 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The proliferation ratio of HCC cells transfected with TERT-siRNA was significantly decreased compared with control group.
|
29707886 |
2018 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The analysis of the Cancer Genome Atlas (TCGA)<sup>4</sup> dataset showed that higher levels of TERT and DNMT3B expression predicted significantly shorter survival in HCC patients.
|
30017965 |
2018 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
High blood levels of malondialdehyde, total antioxidant capacity, caspase-cleaved cytokeratin-18, soluble CD40 ligand, substance P, C-reactive protein, and vascular endothelial growth factor, increased neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in blood, high peripheral blood expression of human telomerase reverse transcriptase messenger ribonucleic acid, and high HCC expression of dickkopf-1 have recently been associated with decreased survival rates.
|
30310256 |
2018 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
High PI3Kδ levels in HCC were found to correlate with poor survival rates, with human advanced HCC showing positive correlations between the protein levels of oxidized SERPINA3, PI3Kδ, and TERT.
|
30300952 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The purpose of the present study was to identify major histocompatibility complex class II-restricted helper T cell epitopes derived from human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
|
29405561 |
2018 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our data suggest that TERT promoter mutations can enhance the promoter activity in HCC cell lines expressing PROX1 but are not the predominant mechanism of TERT upregulation in B viral HCC patients, based on the inhibition of PROX1-dependent transcriptional activation by HBx.
|
29987895 |
2018 |
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In summary, constitutional variants resulting in amino acid changes in the telomerase reverse transcriptase were found in a small proportion of patients with cirrhosis-associated HCC.
|
28813500 |
2017 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this study, we pulled down and identified RBFOX3 (RNA binding protein fox-1 homolog 3) as a novel hTERT promoter-binding protein in HCC cells using biotin-streptavidin-agarose pull-down and proteomics approach, and validated it as a regulatory factor for hTERT signaling and tumor growth in HCCs.
|
28839469 |
2017 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The correlation analysis revealed a significantly negative correlation between miR-138 and telomerase reverse transcriptase (TERT) mRNA expression in HCC.
|
28258280 |
2017 |
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
<i>TERT-CLPTM1</i> locus polymorphism (rs401681) is associated with the prognosis of hepatocellular carcinoma.
|
29042796 |
2017 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In contrast, upregulation of CTCF was positively correlated with FOXM1 and TERT expression in clinical HCC biopsies.
|
28862757 |
2017 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this study, we identified hTERTR-FAM96A (human telomerase reverse transcriptase-family with sequence similarity 96 member A) as a new efficient agent for apoptosome-activating and anti-tumor protein and investigated the potential tumor suppressor function in hepatocellular carcinoma.
|
28443470 |
2017 |
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Here we analyzed the TERT promoter status and genotyped the TERT SNPs at rs2736098 and rs2736100 in patients with HCC.
|
28416747 |
2017 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Interestingly immunohistochemical analysis demonstrated a higher positive rate of TERT cytoplasmic localization (95%) than nuclear localization (64%) in HCCs.
|
28460432 |
2017 |
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to examine telomere length and germline hTERT mutations as associated with NAFLD-HCC.
|
28677271 |
2017 |
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We also showed that telomerase reverse transcriptase promoter (TERTp) mutation correlated with telomere shortening in HCC.
|
28833123 |
2017 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
TERT overexpression was the only significant prognostic factor for late IHR in HCC treated with curative resection.
|
28947783 |
2017 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
TERT promotermutations were significantly more frequent in hepatocellular carcinomas related to hepatitis C virus infection (5/6; 83.3%) compared to tumors of other etiologies (P = 0.001).
|
27661004 |
2016 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
TERT protein levels were higher in HCC (n = 28) compared to normal liver tissues (n = 8) (p =0.001), but did not differ between mutated and non-mutated tumor tissues.
|
27056898 |
2016 |
Liver carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Several lines of evidence suggest that this process is involved in liver disease progression: (a) telomere shortening and alterations in the expression of proteins protecting the telomere are associated with cirrhosis and hepatocellular carcinoma; (b) advanced liver damage is a feature of a spectrum of genetic diseases impairing telomere function, and inactivating germline mutations in the telomerase complex (including human Telomerase Reverse Transcriptase (hTERT) and human Telomerase RNA Component (hTERC)) are enriched in cirrhotic patients independently of the etiology; and (c) experimental models suggest that telomerase protects from liver fibrosis progression.
|
26999107 |
2016 |